Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley(Washington State University Spokane), Michael Fried(University of North Carolina at Chapel Hill), Phillip S. Pang(Gilead Sciences (United States)), K. Rajender Reddy(University of Pennsylvania Health System), David Pound(Orthopaedic Research Foundation), Eugene R. Schiff(University of Miami), Stuart C. Gordon(Henry Ford Health System), William T. Symonds(Gilead Sciences (United States)), Mario Chojkier(University of California, San Diego), Paul J. Pockros(Scripps Clinic), Di An(Gilead Sciences (United States)), John G. McHutchison(Gilead Sciences (United States)), Michael J. Ryan(Digestive & Liver Disease Specialists), Vinod K. Rustgi, Eric Lawitz(The University of Texas at San Antonio Health Science Center), Lorenzo Rossaro(University of California Davis Medical Center), Reem Ghalib(Clinical Research Institute), G. Mani Subramanian(National Institutes of Health), David Bernstein, Evguenia S. Svarovskaia(University of Miami), Robert Herring(Quality Research), Robert H. Hyland(Gilead Sciences (United States)), Mitchell L. Shiffman(Bon Secours Health System), Andrew J. Muir(Duke Medical Center), Adrian M. Di Bisceglie
Cited by 1,125
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k